Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Obama - Clinton Disaster -- Ignore unavailable to you. Want to Upgrade?

To: d[-_-]b who wrote (42365)	12/24/2010 2:19:29 PM
From: Cage Rattler	Respond to of 103300

Good reference -- tnx.

To: d[-_-]b who wrote (42365)	12/24/2010 5:14:45 PM
From: DuckTapeSunroof	Respond to of 103300

Studies performed WHERE? (In the US the DEA, not the FDA or NIH, has the absolute ability to block any scientific study of any schedule one drug that it damn well wants to.... and it has swung that axe many, many times.) Usually the only studies that the DEA approves are ones that 'sound like' they are going to investigate or come up with some sort of NEGATIVE effect. Most any and every attempt to study potentially beneficial aspects of the chemistry are BLOCKED by the DEA bureaucracy that is out to preserve it's own powers and jobs.

To: d[-_-]b who wrote (42365)	12/24/2010 5:22:05 PM
From: DuckTapeSunroof	Read Replies (1) \| Respond to of 103300

Missoula District Court: Jury pool in marijuana case stages ‘mutiny’ A funny thing happened on the way to a trial in Missoula County District Court last week. Jurors – well, potential jurors – staged a revolt. They took the law into their own hands, as it were, and made it clear they weren’t about to convict anybody for having a couple of buds of marijuana. Never mind that the defendant in question also faced a felony charge of criminal distribution of dangerous drugs. The tiny amount of marijuana police found while searching Touray Cornell’s home on April 23 became a huge issue for some members of the jury panel. No, they said, one after the other. No way would they convict somebody for having a 16th of an ounce. In fact, one juror wondered why the county was wasting time and money prosecuting the case at all, said a flummoxed Deputy Missoula County Attorney Andrew Paul. District Judge Dusty Deschamps took a quick poll as to who might agree. Of the 27 potential jurors before him, maybe five raised their hands. A couple of others had already been excused because of their philosophical objections. “I thought, ‘Geez, I don’t know if we can seat a jury,’ ” said Deschamps, who called a recess. And he didn’t. During the recess, Paul and defense attorney Martin Elison worked out a plea agreement. That was on Thursday. On Friday, Cornell entered an Alford plea, in which he didn’t admit guilt. He briefly held his infant daughter in his manacled hands, and walked smiling out of the courtroom. “Public opinion, as revealed by the reaction of a substantial portion of the members of the jury called to try the charges on Dec. 16, 2010, is not supportive of the state’s marijuana law and appeared to prevent any conviction from being obtained simply because an unbiased jury did not appear available under any circumstances,” according to the plea memorandum filed by his attorney. “A mutiny,” said Paul. “Bizarre,” the defense attorney called it. In his nearly 30 years as a prosecutor and judge, Deschamps said he’s never seen anything like it. ***** “I think that’s outstanding,” John Masterson, who heads Montana NORML (National Organization for the Reform of Marijuana Laws), said when told of the incident. “The American populace over the last 10 years or so has begun to believe in a majority that assigning criminal penalties for the personal possession of marijuana is an unjust and a stupid use of government resources.” Masterson is hardly an unbiased source. On the other hand, prosecutor, defense attorney and judge all took note that some of the potential jurors expressed that same opinion. “I think it’s going to become increasingly difficult to seat a jury in marijuana cases, at least the ones involving a small amount,” Deschamps said. The attorneys and the judge all noted Missoula County’s approval in 2006 of Initiative 2, which required law enforcement to treat marijuana crimes as their lowest priority – and also of the 2004 approval of a statewide medical marijuana ballot initiative. And all three noticed the age of the members of the jury pool who objected. A couple looked to be in their 20s. A couple in their 40s. But one of the most vocal was in her 60s. “It’s kind of a reflection of society as a whole on the issue,” said Deschamps. Which begs a question, he said. Given the fact that marijuana use became widespread in the 1960s, most of those early users are now in late middle age and fast approaching elderly. Is it fair, Deschamps wondered, in such cases to insist upon impaneling a jury of “hardliners” who object to all drug use, including marijuana? “I think that poses a real challenge in proceeding,” he said. “Are we really seating a jury of their peers if we just leave people on who are militant on the subject?”.... billingsgazette.com

To: d[-_-]b who wrote (42365)	12/24/2010 5:29:55 PM
From: DuckTapeSunroof	1 Recommendation Respond to of 103300

Recent Research on Medical Marijuana Emerging Clinical Applications For Cannabis & Cannabinoids A Review of the Recent Scientific Literature, 2000 — 2010 norml.org -------------------------------------------------------- Med Res Rev. 2009 Mar;29(2):213-71. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Hanus LO. Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Faculty of Medicine, Hebrew University, Jerusalem, Israel. lumir@cc.huji.ac.il Abstract Research on the chemistry and pharmacology of cannabinoids and endocannabinoids has reached enormous proportions, with approximately 15,000 articles on Cannabis sativa L. and cannabinoids and over 2,000 articles on endocannabinoids. The present review deals with the history of the Cannabis sativa L. plant, its uses, constituent compounds and their biogeneses, and similarity to compounds from Radula spp. In addition, details of the pharmacology of natural cannabinoids, as well as synthetic agonists and antagonists are presented. Finally, details regarding the pioneering isolation of the endocannabinoid anandamide, as well as the pharmacology and potential therapeutic uses of endocannabinoid congeners are presented. (c) 2008 Wiley Periodicals, Inc. PMID: 18777572 [PubMed - indexed for MEDLINE] ncbi.nlm.nih.gov [NOTE: the vast bulk of this modern research was conducted overseas....] ----------------------------------------- Medical Marijuana Reports norml.org